TORONTO – The Centre for Aging + Brain Health Innovation (CABHI) is now accepting applications for the third round of the Industry Innovation Partnership Program (I2P2). The I2P2 provides an opportunity for companies around the world to accelerate their seniors’ care innovations by testing them in a real-world environment. In total, up to $3 million in funding will be available for solution testing and validation.

CABHI maintains a strong commitment to the cognitive and mental well-being of older adults, and the health and social care needs of persons with dementia, and those who care for them, by supporting innovations that are aimed at finding solutions to the following care priorities:

• Aging in place: solutions that enable older adults with dementia to maximize their choices, independence and quality of life to enable aging in the most appropriate setting
• Caregiver support: solutions that support caregivers (formal and informal) in providing care to older adults with dementia
• Care coordination and navigation: solutions that help older adults, caregivers and healthcare providers coordinate care and transitions for older adults with dementia
• Cognitive health: solutions that focus on health promotion, prevention, early diagnostics, and slow the progression of cognitive impairment for aging adults

Applicants must have a mature product or service that they would like to test with older adults at an eligible North American trial partner site. CABHI will provide 50 percent of the project costs to a maximum of $500,000 to the trial partner site to work with the company, and to test and validate the company’s product or service. Successful applicants will be required to co-invest 50 percent of the project costs through cash and in-kind support.

All projects must be completed within a 12 to 15-month period. Eligible applicants must submit their online application by 5 p.m. on March 12, 2018. Full details and selection criteria are available on the CABHI website. (http://www.cabhi.com/i2p2round3/)

Funding for this program is provided by the Government of Canada through the Public Health Agency of Canada, the Government of Ontario through the Ministry of Research, Innovation and Science, and the Baycrest Foundation.